| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- Lesinurad Sodium
-
-
2026-09-11
- CAS:1151516-14-1
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Lesinurad Sodium.
-
-
2026-09-11
- CAS:1151516-14-1
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Lesinurad sodium
-
- $47.00
-
2026-07-27
- CAS:1151516-14-1
- Purity: 99.97%
- Supply Ability: 10g
|
| | RDEA-594 sodiuM Basic information |
| Product Name: | RDEA-594 sodiuM | | Synonyms: | Lesinurad sodiuM;RDEA-594 sodiuM;Acetic acid, 2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-, sodium salt (1:1);sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate;Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-, sodium salt;Sodium 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3- yl)sulfanyl)acetate;CS-651;Pentanedioicacid,5-oxo-,diethylester | | CAS: | 1151516-14-1 | | MF: | C17H13BrN3O2S.Na | | MW: | 426.26279 | | EINECS: | | | Product Categories: | | | Mol File: | 1151516-14-1.mol |  |
| | RDEA-594 sodiuM Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:55.5(Max Conc. mg/mL);137.97(Max Conc. mM)
Ethanol:85.0(Max Conc. mg/mL);199.41(Max Conc. mM)
Water:8.0(Max Conc. mg/mL);18.77(Max Conc. mM) | | form | Solid | | color | White to off-white |
| | RDEA-594 sodiuM Usage And Synthesis |
| Uses | Lesinurad sodium is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 μM, respectively. | | in vivo | Lesinurad (RDEA594) shows better pharmacokinetics than its pro-drug RDEA806. The 100 mg dose of Lesinurad exhibits a phamacological effect in the range of that produced by 300 mg to 800 mg single doses of RDEA806[3]. | | References | [1] Shen Z, et al. In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters. Clin Drug Investig. 2016 Jun;36(6):443-52 DOI:10.1037//0882-7974.4.4.471
[2] Sattui SE, et al. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):145-59. DOI:10.1177/1759720X16646703
[3] L.Yeh, et al. RDEA594, a potential uric acid lowering agent througn inhibition of uric acid reuptake ,shows better pharmacokinetics rhan its prodrug RDEA806. 2008 ACR/ARHP Annual Scientific Meeting, 24-29 October 2008, USA. |
| | RDEA-594 sodiuM Preparation Products And Raw materials |
|